Contribute Try STAT+ Today

Good morning! Katie Palmer here, tagging in for Ed Silverman as he embraces the final days of summer before the onslaught of pumpkin spice everything. Me, I’m settling into my morning with my boring but effective mug of Guatemalan beans — later today I’ll walk down to the roasters to pick up my next five-pound bag. Here’s hoping your day gets off to a caffeinated and productive start. And to help you on your way, here’s what’s happening. …

A second dose of the Covid-19 vaccine from Johnson & Johnson (JNJ) strongly increased antibody levels, according to provisional data from two early-stage trials, the New York Times reports. The results, issued in a press release by the company, showed that binding antibodies were nine times higher after a second shot given six months after the first. J&J plans to submit the results to the Food and Drug Administration to evaluate its inclusion in the U.S. plan for booster shots.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment